Scientia, Dipòsit d’Informació Digital del Departament de Salut
Not a member yet
12576 research outputs found
Sort by
En què m'he de fixar quan compro una mascareta? [cartell]
No full textMalalties respiratòries; Mascaretes; Tipologia; ÚsEnfermedades respiratorias; Mascarillas; Tipología; UsoRespiratory diseases; Masks; Type; UseCartell adreçat a la ciutadania informant sobre els tipus de mascaretes i com fer-ne un ús adequat per protegir-se de les infeccions respiratòries
La preparación de biberones
Get PDFSeguretat alimentària; Biberons; ConsellsSeguridad alimentaria; Biberones; ConsejosFood safety; Baby bottles; TipsAquest document ofereix pautes segures per preparar biberons, destacant la higiene i dos mètodes: amb aigua calenta (més segura) i amb aigua freda. També adverteix sobre microorganismes perillosos i la importància de no reutilitzar la llet sobrant.Este documento ofrece pautas seguras para preparar biberones, destacando la higiene y dos métodos: con agua caliente (más seguro) y con agua fría. También advierte sobre microorganismos peligrosos y la importancia de no reutilizar la leche sobrante.This document provides safe guidelines for preparing baby bottles, emphasizing hygiene and two methods: with hot water (safer) and cold water. It also warns about dangerous microorganisms and the importance of not reusing leftover milk
La seguridad alimentaria para las personas mayores
Get PDFGent gran; Alimentació; ConsellsGente mayor; Alimentación; ConsejosAged; Feeding; AdvicesFicha que ofrece consejos sobre la alimentación de las personas mayoresFitxa que ofereix consells sobre l'alimentació de la gent gran.Sheet that offers advice on nutrition for the elderl
TRBC1-CAR T cell therapy in peripheral T cell lymphoma: a phase 1/2 trial
Get PDFCAR T cell therapy; Peripheral T cell lymphomaTeràpia de cèl·lules T; Limfoma perifèric de cèl·lules TTerapia de células T; Linfoma periférico de células TRelapsed/refractory peripheral T cell lymphomas (PTCLs) are aggressive tumors with a poor prognosis. Unlike B cell lymphomas, treatment of PTCL has not benefited from advances in immunotherapy. This is largely due to a lack of suitable target antigens that discriminate malignant from normal T cells, thus avoiding severe immunosuppression consequent to depletion of the entire T cell compartment. We recently described a targeting strategy based on the mutually exclusive expression of T cell antigen receptor beta-chain constant domain (TRBC) 1 and 2. Selective targeting of the T cell antigen receptor beta-chain expressed by the (clonal) malignancy spares normal T cells expressing the other chain. The LibraT1 study is an ongoing, multicenter, international, single-arm phase 1/2 study of TRBC1-directed autologous chimeric antigen receptor (CAR) T cells (AUTO4) in relapsed/refractory TRBC1-positive PTCL. Primary objectives were assessment of safety and tolerability of AUTO4 infusion. Key secondary endpoints included efficacy, CAR T cell expansion and persistence. Here we describe the findings from dose escalation in LibraT1 in the first ten patients, in a non-prespecified interim analysis. AUTO4 resulted in low frequency of severe immunotoxicity, with one of ten patients developing grade 3 cytokine release syndrome. Complete metabolic response was observed in four of ten evaluable patients, with remissions being durable beyond 1 year in two patients. While an absence of circulating CAR T cells was observed, CAR T cells were readily detected in lymph node biopsy samples from sites of original disease suggesting homing to tumor sites. These results support the continuing exploration of TRBC1 targeting in PTCL. ClinicalTrials.gov registration: NCT03590574.This study was funded by Autolus Therapeutics and Innovate UK (grant TS/N010167/1). We are indebted to the patients and their families for their commitment. We thank all the clinical investigators, research nurses and study coordinators. We also acknowledge the contribution of the Independent Data Monitoring Committee members
Epidemiología de la enfermedad invasiva por Listeria monocytogenes en Cataluña. Informe 2022-2023
Get PDFListeria monocytogenes; Malaltia bacteriana; AlimentsListería monocytogenes; Enfermedad bacteriana;Listeria monocytogenes; Bacterial disease; FoodsL’objectiu d’aquest informe és descriure les característiques clíniques i
epidemiològiques dels casos confirmats de listeriosi invasiva declarats en el
sistema de notificació microbiològica de Catalunya (SNMC) de la Subdirecció
General de Vigilància i Resposta a Emergències de Salut Pública (SGVRESP) en
el període 2022-2023.The aim of this report is to describe the clinical characteristics and
epidemiological of confirmed cases of invasive listeriosis statements in the
microbiological notification system of Catalonia (SNMC) of the Subdirectorate
General Surveillance and Response to Public Health Emergencies (SGVRESP) en
the period 2022-2023.El objetivo de este informe es describir las características clínicas y
epidemiológicas de los casos confirmados de listeriosis invasiva declaraciones en el
sistema de notificación microbiológica de Cataluña (SNMC) de la Subdirección
General de Vigilancia y Respuesta a Emergencias de Salud Pública (SGVRESP) en
el período 2022-2023
Enhancing Tumor Microstructural Quantification With Machine Learning and Diffusion-Relaxation MRI
Get PDFCuantificación microestructural de tumores; Aprendizaje automático; Resonancia magnética de difusión-relajaciónQuantificació microestructural del tumor; Aprenentatge automàtic; Ressonància magnètica de difusió-relaxacióTumor microstructural quantification; Machine learning; Diffusion-relaxation magnetic resonance imagingWe thank the whole medical oncology, radiology, pathology, molecular biology, clinical trial, and IT teams at the Vall d'Hebron Campus. We would also like to express our sincere gratitude to all patients and their families for dedicating their time to research. VHIO acknowledges the State Agency for Research (Agencia Estatal de Investigación) for the financial support as a Center of Excellence Severo Ochoa (CEX2020-001024-S/AEI/10.13039/501100011033), the Cellex Foundation for providing research facilities and equipment and the CERCA Programme from the Generalitat de Catalunya for their support. This research has been supported by PREdICT, sponsored by AstraZeneca. This study has been co-funded by the European Regional Development Fund/European Social Fund “A way to make Europe” (to R.P.L.). RPL is supported by “la Caixa” Foundation, the Prostate Cancer Foundation (18YOUN19), a CRIS Foundation Talent Award (TALENT19-05), the FERO Foundation through the XVIII Fero Fellowship for Oncological Research, the Instituto de Salud Carlos III-Investigación en Salud (PI18/01395 and PI21/01019), the Asociación Española Contra el Cancer (AECC) (PRYCO211023SERR) and the Agency for Management of University and Research Grants of Catalonia (AGAUR) (2023PROD00178). This research has been funded by the CaixaResearch Advanced Oncology Research Program supported by “La Caixa” Foundation (to R.P.L.). The project that gave rise to these results received the support of a fellowship from “la Caixa” Foundation (ID 100010434). The fellowship code is “LCF/BQ/PR22/11920010”, funding F.G. This research has received support from the Beatriu de Pinós Postdoctoral Program from the Secretariat of Universities and Research of the Department of Business and Knowledge of the Government of Catalonia, and the support from the Marie Sklodowska-Curie COFUND program (BP3, contract number 801370; reference 2019 BP 00182) of the H2020 program (to K.B.). C.M. is supported by the Asociación Española Contra el Cancer (PRYCO211023SERR). VHIO is also grateful to the Generalitat de Catalunya, Comissió Interdepartamental de Recerca i Innovació Tecnològica
Ús de fàrmacs hipoglucemiants en pacients fràgils polimedicats [fullet]
Get PDFControl glucèmic; Medicaments; Diabetis mellitus de tipus 2Control glucémico; Medicamentos; Diabetes mellitus de tipo 2Glycemic control; Medicines; Type 2 diabetes mellitusInfografia orientada a professionals amb recomanacions sobre l'ús de fàrmacs hipoglucemiants.Infografía orientada a profesionales con recomendaciones sobre el uso de fármacos hipoglucemiantes.Infographic aimed at professionals with recommendations on the use of hypoglycemic drugs
International Multicenter Retrospective Study From the Ultra-rare Sarcoma Working Group on Low-grade Fibromyxoid Sarcoma, Sclerosing Epithelioid Fibrosarcoma, and Hybrid Forms: Outcome of Primary Localized Disease
Get PDFLow-grade fibromyxoid sarcoma; Sclerosing epithelioid fibrosarcomaSarcoma fibromixoide de baix grau; Fibrosarcoma epitelioide esclerosantSarcoma fibromixoide de bajo grado; Fibrosarcoma epitelioide esclerosanteThe aim of the study was to report the outcome of primary localized low-grade fibromyxoid sarcoma (LGFMS), sclerosing epithelioid fibrosarcoma (SEF), and hybrid LGFMS/SEF (H-LGFMS/SEF). Patients with primary localized LGFMS, SEF, or H-LGFMS/SEF, surgically treated with curative intent from January 2000 to September 2022, were enrolled from 14 countries and 27 institutions. Pathologic inclusion criteria were predefined by expert pathologists. The primary endpoint was overall survival (OS). Secondary endpoints were crude cumulative incidence (CCI) of local recurrence (LR), CCI of distant metastases (DM), and post-metastases OS (p-OS). Two hundred ninety-four patients (239 LGFMS, 32 SEF, and 23 H-LGFMS/SEF) were identified. At a median(m-) follow-up (FU) of 57.1 months, 12/294 patients died. The 5- and 10-year OS were 99.0% and 95.9% in LGFMS, 86.2% and 67.0% in SEF, and 84.8% and 84.8% in H-LGFMS/SEF, respectively. Predictors of worse OS included pathology, age at surgery, systemic therapy, and radiotherapy. LR developed in 13/294 (4.4%) patients. The observed m-time to LR was 10.7 months. The 5- and 10-yr CCI-LR were 4.7% in LGFMS and 6.6% in SEF, respectively. There were no LR events in H-LGFMS/SEF. The sole predictor of higher risk of LR was histology. DM developed in 23/294 (7.8%) patients. The observed m-time to DM was 28.2 months. The 5- and 10-yr CCI-DM were 1.3% and 2.7% in LGMFS, 29.9% and 57.7% in SEF, 48.9% and 48.9% in H-LGFMS/SEF, respectively. Predictors of higher risk of DM were histology, systemic therapy, and radiotherapy. Primary localized LGFMS treated with complete surgical resection has an excellent prognosis, while about 50% of H-LGFMS/SEF and SEF develop DM within 5 to 10 years. Very long-term FU is needed to understand absolute cure rates.The cost was partially supported by funding from the Italian Ministry of Health, Ricerca Corrente and 5×1000 funds for health care research
Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine
Get PDFImmunotherapy; Pleural mesothelioma; Telomerase vaccineInmunoterapia; Mesotelioma pleural; Vacuna de telomerasaImmunoteràpia; Mesotelioma pleural; Vacuna de telomerasaPurpose
The introduction of immunotherapy in pleural mesothelioma (PM) has highlighted the need for effective outcome predictors. This study explores the role of [18F]FDG PET/CT in predicting outcomes in PM treated with immunotherapy.
Methods
Patients from the NIPU trial, receiving ipilimumab and nivolumab +/- telomerase vaccine in second-line, were included. [18F]FDG PET/CT was obtained at baseline (n = 100) and at week-5 (n = 76). Metabolic tumour volume (MTV) and peak standardised uptake value (SUVpeak) were evaluated in relation to survival outcomes. Wilcoxon rank-sum test was used to assess differences in MTV, total lesion glycolysis (TLG), maximum standardised uptake value (SUVmax) and SUVpeak between patients exhibiting an objective response, defined as either partial response or complete response according to the modified Response Criteria in Solid Tumours (mRECIST) and immune RECIST (iRECIST), and non-responders, defined as either stable disease or progressive disease as their best overall response.
Results
Univariate Cox regression revealed significant associations of MTV with OS (HR 1.36, CI: 1.14, 1.62, p < 0.001) and PFS (HR 1.18, CI: 1.03, 1.34, p = 0.02), while multivariate analysis showed a significant association with OS only (HR 1.35, CI: 1.09, 1.68, p = 0.007). While SUVpeak was not significantly associated with OS or PFS in univariate analyses, it was significantly associated with OS in multivariate analysis (HR 0.43, CI: 0.23, 0.80, p = 0.008). Objective responders had significant reductions in TLG, SUVmax and SUVpeak at week-5.
Conclusion
MTV provides prognostic value in PM treated with immunotherapy. High SUVpeak was not associated with inferior outcomes, which could be attributed to the distinct mechanisms of immunotherapy. Early reductions in PET metrics correlated with treatment response.
Study registration
The NIPU trial (NCT04300244) is registered at clinicaltrials.gov. https://classic.clinicaltrials.gov/ct2/show/NCT04300244?cond=Pleural+Mesothelioma&cntry=NO&draw=2&rank=4Open access funding provided by University of Oslo (incl Oslo University Hospital). The trial was researcher-initiated and funded by grants from the South-Eastern Norway Regional Health Authorities (grant number 2020077 and 2021083). Study medication was provided by Ultimovacs and Bristol Myers Squibb. Ultimovacs also provided funding for study procedures
Development of a multiple urinary biomarker model to predict the tubulointerstitial fibrosis area in patients with primary IgA Nephropathy
Get PDFIgA nephropathy; Renal fibrosis; Urinary biomarkersNefropatia per IgA; Fibrosi renal; Biomarcadors urinarisNefropatía por IgA; Fibrosis renal; Biomarcadores urinariosBackground: Previous studies highlighted the utility of individual urinary biomarkers in the prediction of interstitial fibrosis in IgA Nephropathy patients. However, it´s uncertain which biomarker or combination of biomarkers provides a more accurate estimation of renal interstitial fibrosis Surface. Herein, we measured the urinary excretion of a set of seven tubular injury biomarkers in a group of patients with primary IgA Nephropathy and analyzed their utility as non-invasive estimators of interstitial fibrosis area found on kidney biopsy.
Methods: Two hundred forty-seven adults with primary IgA Nephropathy diagnosed by kidney biopsy and a control group of 50 healthy control were included. The urinary excretion of EGF, MCP-1, NGAL, KIM-1, L-FABP, β2-microglobulin and DKK-3 was measured in urine samples collected at the day of the renal biopsy. Estimated glomerular filtration rate was measured by the CKD-EPI formula. Interstitial fibrosis area was quantified using a quantitative morphometric procedure and graded according to Oxford Classification. Predictive multivariate models were developed to predict the interstitial fibrosis surface.
Results: Patients with primary IgA Nephropathy showed significantly higher urinary levels of DKK-3, L-FABP and β2-microglobulin, and lower EGF levels than healthy controls. Interstitial fibrosis was negatively correlated with urinary EGF levels and positively with age, proteinuria, eGFR and urinary DKK-3, L-FABP and β2-microglobulin. The best model to predict interstitial fibrosis area accounted for > 60% of its variability and included age, eGFR, proteinuria, DKK-3, EGF, L-FABP and β2-microglobulin.
Conclusions: Our study provides a model to estimate the IFS in IgA Nephropathy which could be useful to monitor the progression of chronic kidney injury